Derek P Narendra

List of Publications by Year
in descending order

41 papers	23,347 citations	346980 22 h-index	355658 38 g-index
47 all docs	47 docs citations	47 times ranked	34916 citing authors

#	Article	IF	Citations
1	Heterozygous <i>PRKN</i> mutations are common but do not increase the risk of Parkinsonâ€™s disease. Brain, 2022, 145, 2077-2091.	3.7	26
2	Sorting out Parkinsonâ€™s disease: one cell at a time. Brain, 2022, , .	3.7	0
3	OMA1 mediates local and global stress responses against protein misfolding in CHCHD10 mitochondrial myopathy. Journal of Clinical Investigation, 2022, 132, .	3.9	24
4	Mitochondrial Dysfunction and Mitophagy in Parkinsonâ€™s Disease: From Mechanism to Therapy. Trends in Biochemical Sciences, 2021, 46, 329-343.	3.7	234
5	Mt-Keima detects PINK1-PRKN mitophagy <i>in vivo</i> with greater sensitivity than mito-QC. Autophagy, 2021, 17, 3753-3762.	4.3	28
6	Comment on â€œmt-Keima detects PINK1-PRKN mitophagy <i>in vivo</i> with greater sensitivity than mito-QCâ€. Autophagy, 2021, 17, 4484-4485.	4.3	4
7	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	2.8	29
8	<scp>Î±â€Synuclein</scp> Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease. Movement Disorders, 2021, 36, 2346-2357.	2.2	11
9	Discovery of bactericides as an acute mitochondrial membrane damage inducer. Molecular Biology of the Cell, 2021, 32, ar32.	0.9	6
10	Managing risky assets â€“ mitophagy <i>in vivo</i>. Journal of Cell Science, 2021, 134, .	1.2	11
11	Finding genetically-supported drug targets for Parkinsonâ€™s disease using Mendelian randomization of the druggable genome. Nature Communications, 2021, 12, 7342.	5.8	44
12	Coupling APEX labeling to imaging mass spectrometry of single organelles reveals heterogeneity in lysosomal protein turnover. Journal of Cell Biology, 2020, 219, .	2.3	18
13	Metabolic Analysis at the Nanoscale with Multiâ€Isotope Imaging Mass Spectrometry (MIMS). Current Protocols in Cell Biology, 2020, 88, e111.	2.3	6
14	Author response: Peripheral synucleinopathy in a DJ1 patient with Parkinson disease, cataracts, and hearing loss. Neurology, 2020, 94, 944.1-944.	1.5	0
15	Detection of mitophagy in mammalian cells, mice, and yeast. Methods in Cell Biology, 2020, 155, 557-579.	0.5	4
16	Penetrance of Parkinson's Disease in <i>LRRK2</i> p.G2019S Carriers Is Modified by a Polygenic Risk Score. Movement Disorders, 2020, 35, 774-780.	2.2	57
17	Loss of CHCHD2 and CHCHD10 activates OMA1 peptidase to disrupt mitochondrial cristae phenocopying patient mutations. Human Molecular Genetics, 2020, 29, 1547-1567.	1.4	42
18	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	4.9	1,414

#	Article	IF	Citations
19	Peripheral synucleinopathy in a DJ1 patient with Parkinson disease, cataracts, and hearing loss. Neurology, 2019, 92, 1113-1115.	1.5	14
20	CHCHD2 accumulates in distressed mitochondria and facilitates oligomerization of CHCHD10. Human Molecular Genetics, 2018, 27, 3881-3900.	1.4	38
21	Parkin and PINK1 mitigate STING-induced inflammation. Nature, 2018, 561, 258-262.	13.7	905
22	A Woman in Her 40s With Headache and New-Onset Seizures. JAMA Neurology, 2017, 74, 476.	4.5	0
23	PARKIN/PINK1 Pathway for the Selective Isolation and Degradation of Impaired Mitochondria. , 2016, , 159-182.		3
24	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
25	An anomalous developmental venous anomaly. Neurology, 2014, 83, 1033-1034.	1.5	3
26	Teaching Neuro <i>Images</i> : Brain mass with hilar adenopathy. Neurology, 2014, 82, e161-2.	1.5	2
27	PINK1 rendered temperature sensitive by disease-associated and engineered mutations. Human Molecular Genetics, 2013, 22, 2572-2589.	1.4	23
28	PINK1 drives Parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. Journal of Cell Biology, 2013, 200, 163-172.	2.3	209
29	Mitochondrial Quality Control Mediated by PINK1 and Parkin: Links to Parkinsonism. Cold Spring Harbor Perspectives in Biology, 2012, 4, a011338-a011338.	2.3	273
30	Trouble in the cell's powerhouse. Nature, 2012, 483, 418-419.	13.7	22
31	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
32	Mechanisms of mitophagy. Nature Reviews Molecular Cell Biology, 2011, 12, 9-14.	16.1	2,638
33	Targeting Mitochondrial Dysfunction: Role for PINK1 and Parkin in Mitochondrial Quality Control. Antioxidants and Redox Signaling, 2011, 14, 1929-1938.	2.5	330
34	Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11835-11840.	3.3	286
35	p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. Autophagy, 2010, 6, 1090-1106.	4.3	663
36	Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. Journal of Cell Biology, 2010, 191, 933-942.	2.3	1,078

#	Article	IF	Citations
37	Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. Journal of Cell Biology, 2010, 191, 1367-1380.	2.3	1,161
38	PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin. PLoS Biology, 2010, 8, e1000298.	2.6	2,299
39	Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy, 2009, 5, 706-708.	4.3	209
40	Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. Journal of Cell Biology, 2008, 183, 795-803.	2.3	3,315
41	When Patients Lack Capacity: The Roles That Patients with Terminal Diagnoses Would Choose for Their Physicians and Loved Ones in Making Medical Decisions. Journal of Pain and Symptom Management, 2005, 30, 342-353.	0.6	76